MOR-106

• Description :

  MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C) . MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis[1][2].

• Product Name Alternative :

  MOR12743; MOR03207

• UNSPSC :

  12352203

• Target :

  Interleukin Related; NF-κB

• Related Pathways :

  Immunology/Inflammation; NF-κB

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• References & Citations :

  [1]Vandeghinste N, et al. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. J Invest Dermatol. 2018 Jul;138 (7) :1555-1563. |[2]Lauffer F, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020 Apr;34 (4) :800-809.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported

• Isoform :

  IL-17; NF-κB

• CAS Number :

  [2304625-87-2]